Sanjivani Paranteral Ltd, a pharmaceutical powerhouse based in Mumbai, has announced remarkable financial results for Q2 of the fiscal year 2025, showcasing significant growth across revenue and profitability metrics. With a year-on-year revenue increase of 29.5%, the company has reinforced its leadership in manufacturing parenteral and oral solid products, particularly in therapeutic areas such as central nervous system (CNS), cardiovascular system (CVS), antibiotics, gastroenterological, anti-diabetics, and anti-allergic medications.

In its latest press release, the company disclosed a revenue jump from INR 141.5 million in Q2 FY24 to INR 181.3 million in Q2 FY25. This leap is further underscored by an improved EBITDA margin, rising by 171 basis points to 17.9%, driven by heightened operational efficiencies. Sanjivani Paranteral Ltd also reported a steady rise in Profit After Tax (PAT) margins, which reached 12.4% for the quarter.

A Strong Performance Across Key Markets and Product Segments

Sanjivani Paranteral Ltd’s revenue growth has been bolstered by its strategic focus on core international markets, including the Commonwealth of Independent States (CIS) region, the Middle East, and Latin America, which collectively account for over 81% of the company’s revenue. These regions contributed INR 147.4 million to the quarter’s total revenue, reflecting Sanjivani’s intensified export-oriented approach. Export operations, inclusive of incentives, now make up 81.3% of the company’s total revenue, leaving a domestic market share of 18.8%.

The company’s injectables segment saw revenue growth of 21.9% year-on-year, contributing INR 90.7 million, while the oral segment increased by 10.3%, amounting to INR 77.3 million. Nutraceuticals, though a smaller portion of the portfolio, generated INR 13.4 million in revenue, illustrating diversified growth across multiple product lines.

Leadership Perspective on Sanjivani’s Strategic Direction

Ashwani Khemka, Chairman and Managing Director of Sanjivani Paranteral Ltd, expressed optimism about the company’s achievements, attributing the quarter’s success to a firm commitment to quality, innovation, and a strengthening operational framework. Khemka emphasised that the company is diligently expanding its research and development capabilities to further its presence in key international markets, including the CIS, Middle East, and Latin America, aimed at sustaining long-term growth. He highlighted that these efforts align with Sanjivani’s vision to bring value to its customers and shareholders, setting a foundation for continuous progress within the global pharmaceutical landscape.

Solid Financial Performance Marks H1 FY25

For the first half of FY25, Sanjivani Paranteral Ltd reported a revenue boost of 30% year-on-year, totalling INR 345.7 million. Its EBITDA margin for H1 FY25 reached 16.4%, while PAT witnessed a 23.2% year-on-year growth to INR 40.1 million, with a PAT margin of 11.4%.

Segment-wise, the injectables segment reported a minor year-on-year decline of 1.9%, generating INR 152.5 million, whereas the oral segment marked an impressive 45% growth, amounting to INR 175.9 million for H1. Nutraceuticals contributed INR 17.3 million, highlighting a steady expansion across diverse therapeutic categories. The company’s core markets have been pivotal in this growth, with CIS and Latin America regions jointly making up 84.6% of H1 FY25’s revenue, reflecting the company’s proactive export-driven strategy.

Financial Expert Opinion: Positioning for Sustained Growth

Financial analysts highlight Sanjivani Paranteral Ltd’s robust quarter as a clear sign of the company’s strengthening market presence amidst challenging conditions in the global pharmaceutical sector. Experts suggest that the company’s prioritisation of export markets, particularly in the CIS and Latin American regions, is a significant factor underpinning its sustained revenue growth. Moreover, they note that the company’s focused R&D investments signal Sanjivani’s commitment to pioneering developments in parenteral and oral solid formulations, a move that could further secure its position in high-demand markets.

  Ashwani Khemka, CIS, India, Latin America, Middle East, Mumbai, pharmaceuticals, Sanjivani Paranteral Ltd